Application of FDG-PET/CT in Radiation Oncology

doi:10.3389/fonc.2013.00080

. 2013 Apr 11:3:80.

doi: 10.3389/fonc.2013.00080. eCollection 2013.

Application of FDG-PET/CT in Radiation Oncology

Jun Li¹, Ying Xiao

Affiliations

PMID: 23596565
PMCID: PMC3622875
DOI: 10.3389/fonc.2013.00080

Application of FDG-PET/CT in Radiation Oncology

Jun Li et al. Front Oncol. 2013.

. 2013 Apr 11:3:80.

doi: 10.3389/fonc.2013.00080. eCollection 2013.

Authors

Jun Li¹, Ying Xiao

Affiliation

¹ Department of Radiation Oncology, Thomas Jefferson University Philadelphia, PA, USA.

PMID: 23596565
PMCID: PMC3622875
DOI: 10.3389/fonc.2013.00080

Abstract

Positron emission tomography (PET)/computed tomography (CT), which combines the advantages of high sensitivity and specificity of PET and high resolution of CT, is a unique tool for cancer management. PET/CT has been widely used in cancer diagnosis and treatment. The article reviews the recent applications of PET/CT in radiation oncology, with a focus on (18)F-fluorodeoxyglucose (FDG)-PET/CT, addressing the applications in treatment planning and treatment response assessment of radiation therapy.

Keywords: PET/CT; radiation oncology; radiation therapy; treatment planning; treatment response.

PubMed Disclaimer

Cited by

¹⁸F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.
Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK. Korn RL, et al. Cancer Imaging. 2017 Aug 3;17(1):23. doi: 10.1186/s40644-017-0125-5. Cancer Imaging. 2017. PMID: 28774338 Free PMC article. Clinical Trial.
Combined pretreatment with ¹⁸F-FDG PET/CT and Comet assay guides the concurrent chemoradiotherapy of locally advanced cervical cancer: study protocol for a randomized controlled trial.
Ji S, Hu Q, Zhu J, Chen J, Chen Q, Liu Z, Shen C, Yang R, Sun H, Wu J, Gu K. Ji S, et al. Trials. 2018 Aug 3;19(1):416. doi: 10.1186/s13063-018-2800-7. Trials. 2018. PMID: 30075736 Free PMC article.
Use of (18)F-FDG PET/CT to locate primary malignancies in patients with hepatic cirrhosis and malignant ascites.
Fan HB, Wang AJ, Yang DL, Xiao J, Ai Y, Huang L, Guo Y, Zhou MX, Wu JJ, Li Z, Yan FM, Wang YM. Fan HB, et al. Chin J Cancer Res. 2013 Oct;25(5):500-4. doi: 10.3978/j.issn.1000-9604.2013.09.01. Chin J Cancer Res. 2013. PMID: 24255572 Free PMC article.
The role of imaging in radiation therapy planning: past, present, and future.
Pereira GC, Traughber M, Muzic RF Jr. Pereira GC, et al. Biomed Res Int. 2014;2014:231090. doi: 10.1155/2014/231090. Epub 2014 Apr 10. Biomed Res Int. 2014. PMID: 24812609 Free PMC article. Review.
Comparison of rigid and deformable image registration for nasopharyngeal carcinoma radiotherapy planning with diagnostic position PET/CT.
Kai Y, Arimura H, Toya R, Saito T, Matsuyama T, Fukugawa Y, Shiraishi S, Shimohigashi Y, Maruyama M, Oya N. Kai Y, et al. Jpn J Radiol. 2020 Mar;38(3):256-264. doi: 10.1007/s11604-019-00911-6. Epub 2019 Dec 13. Jpn J Radiol. 2020. PMID: 31834577

References

1. Bettinardi V., Picchio M., Di Muzio N., Gilardi M. C. (2012). Motion management in positron emission tomography/computed tomography for radiation treatment planning. Semin. Nucl. Med. 42, 289–30710.1053/j.semnuclmed.2012.04.001 - DOI - PubMed
1. Borst G. R., Belderbos J. S., Boellaard R., Comans E. F., De Jaeger K., Lammertsma A. A., et al. (2005). Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur. J. Cancer 41, 1533–154110.1016/j.ejca.2005.03.026 - DOI - PubMed
1. Bradley J. D., Perez C. A., Dehdashti F., Siegel B. A. (2004). Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45(Suppl. 1), 96S–101S - PubMed
1. Bussink J., Kaanders J. H., van der Graaf W. T., Oyen W. J. (2011). PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 8, 233–24210.1038/nrclinonc.2010.218 - DOI - PubMed
1. Caldarella C., Salsano M., Isgrò M. A., Treglia G. (2012). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the response to neoadjuvant treatment in patients with osteosarcoma. Int. J. Mol. Imaging 2012, 870301. - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Bettinardi V., Picchio M., Di Muzio N., Gilardi M. C. (2012). Motion management in positron emission tomography/computed tomography for radiation treatment planning. Semin. Nucl. Med. 42, 289–30710.1053/j.semnuclmed.2012.04.001 - DOI - PubMed

[2] Bettinardi V., Picchio M., Di Muzio N., Gilardi M. C. (2012). Motion management in positron emission tomography/computed tomography for radiation treatment planning. Semin. Nucl. Med. 42, 289–30710.1053/j.semnuclmed.2012.04.001 - DOI - PubMed

[3] Borst G. R., Belderbos J. S., Boellaard R., Comans E. F., De Jaeger K., Lammertsma A. A., et al. (2005). Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur. J. Cancer 41, 1533–154110.1016/j.ejca.2005.03.026 - DOI - PubMed

[4] Borst G. R., Belderbos J. S., Boellaard R., Comans E. F., De Jaeger K., Lammertsma A. A., et al. (2005). Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur. J. Cancer 41, 1533–154110.1016/j.ejca.2005.03.026 - DOI - PubMed

[5] Bradley J. D., Perez C. A., Dehdashti F., Siegel B. A. (2004). Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45(Suppl. 1), 96S–101S - PubMed

[6] Bradley J. D., Perez C. A., Dehdashti F., Siegel B. A. (2004). Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45(Suppl. 1), 96S–101S - PubMed

[7] Bussink J., Kaanders J. H., van der Graaf W. T., Oyen W. J. (2011). PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 8, 233–24210.1038/nrclinonc.2010.218 - DOI - PubMed

[8] Bussink J., Kaanders J. H., van der Graaf W. T., Oyen W. J. (2011). PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 8, 233–24210.1038/nrclinonc.2010.218 - DOI - PubMed

[9] Caldarella C., Salsano M., Isgrò M. A., Treglia G. (2012). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the response to neoadjuvant treatment in patients with osteosarcoma. Int. J. Mol. Imaging 2012, 870301. - PMC - PubMed

[10] Caldarella C., Salsano M., Isgrò M. A., Treglia G. (2012). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the response to neoadjuvant treatment in patients with osteosarcoma. Int. J. Mol. Imaging 2012, 870301. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Application of FDG-PET/CT in Radiation Oncology

Affiliation

Application of FDG-PET/CT in Radiation Oncology

Authors

Affiliation

Abstract

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources